Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 16, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	3,505	3,977	4,484	1,862	721	360
Market Cap Growth	25.65%	-11.32%	140.89%	158.23%	100.31%	-12.38%
Enterprise Value	3,008	3,263	3,555	1,487	567	144
Last Close Price	29.95	35.18	40.24	18.61	9.40	4.60

Price Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 16, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PB Ratio	8.56	6.22	5.09	5.34	4.96	1.78
P/TBV Ratio	8.60	6.22	5.09	5.34	4.96	1.78

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 16, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Debt / Equity Ratio	0.01	0	0.00	0.00	0.01	0
Net Debt / Equity Ratio	-1.22	-1.10	-1.02	-1.04	-1.06	-1.00
Quick Ratio	4.58	9.21	32.93	18.92	7.09	23.02
Current Ratio	4.72	9.33	33.09	19.19	7.61	23.98
Return on Equity (ROE)	-88.85%	-47.34%	-17.90%	-34.79%	-39.67%	-24.65%
Return on Assets (ROA)	-51.86%	-30.28%	-14.77%	-23.47%	-23.19%	-14.90%
Return on Capital Employed (ROCE)	-135.80%	-61.50%	-17.10%	-28.90%	-48.00%	-27.60%

Yields

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 16, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Earnings Yield	-15.23%	-9.04%	-2.45%	-4.61%	-9.55%	-15.28%
Buyback Yield / Dilution	-2.64%	-3.33%	-15.57%	-22.79%	0.47%	-6.34%

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Jul 29, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 16, 2026

Data Sources Report a data error